THE USE OF ROMIPLOSTIM IN AN INFANT
Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921012190 |
| _version_ | 1818431229610950656 |
|---|---|
| author | Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI |
| author_facet | Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI |
| author_sort | Fatma Burçin KURTİPEK |
| collection | DOAJ |
| description | Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy. |
| first_indexed | 2024-12-14T15:45:59Z |
| format | Article |
| id | doaj.art-e532f33be60f441e91ddee70a06808f3 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-14T15:45:59Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-e532f33be60f441e91ddee70a06808f32022-12-21T22:55:30ZengElsevierHematology, Transfusion and Cell Therapy2531-13792021-11-0143S56S57THE USE OF ROMIPLOSTIM IN AN INFANTFatma Burçin KURTİPEK0Turan BAYHAN1Vildan ÇULHA2Neşe YARALI3Ankara City HospitalAnkara City HospitalAnkara City HospitalAnkara City HospitalCase report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.http://www.sciencedirect.com/science/article/pii/S2531137921012190 |
| spellingShingle | Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI THE USE OF ROMIPLOSTIM IN AN INFANT Hematology, Transfusion and Cell Therapy |
| title | THE USE OF ROMIPLOSTIM IN AN INFANT |
| title_full | THE USE OF ROMIPLOSTIM IN AN INFANT |
| title_fullStr | THE USE OF ROMIPLOSTIM IN AN INFANT |
| title_full_unstemmed | THE USE OF ROMIPLOSTIM IN AN INFANT |
| title_short | THE USE OF ROMIPLOSTIM IN AN INFANT |
| title_sort | use of romiplostim in an infant |
| url | http://www.sciencedirect.com/science/article/pii/S2531137921012190 |
| work_keys_str_mv | AT fatmaburcinkurtipek theuseofromiplostiminaninfant AT turanbayhan theuseofromiplostiminaninfant AT vildanculha theuseofromiplostiminaninfant AT neseyarali theuseofromiplostiminaninfant AT fatmaburcinkurtipek useofromiplostiminaninfant AT turanbayhan useofromiplostiminaninfant AT vildanculha useofromiplostiminaninfant AT neseyarali useofromiplostiminaninfant |